Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.30 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
| ▸ | CDC25B | P30305 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10834300 | 0.91 | LMNA (0.52) | CYP3A4ALDH1A1TDP1LMNAMEN1 | |
| SCHEMBL13239742 | 0.84 | ALDH1A1 (0.41) | CYP3A4ALDH1A1TDP1LMNATSHR | |
| SCHEMBL11546962 | 0.83 | ALDH1A1 (0.39) | CYP3A4ALDH1A1TDP1LMNATSHR | |
| SCHEMBL8858043 | 0.82 | MEN1 (0.41) | CYP3A4ALDH1A1LMNAMEN1ALOX15 | |
| SCHEMBL11547671 | 0.81 | ALDH1A1 (0.38) | CYP3A4ALDH1A1TDP1LMNATSHR | |
| SCHEMBL19812427 | 0.79 | ALDH1A1 (0.43) | CYP3A4ALDH1A1TDP1LMNAMEN1 | |
| SCHEMBL114177 | 0.79 | ALDH1A1 (0.37) | CYP3A4ALDH1A1TDP1LMNATSHR | |
| SCHEMBL5322857 | 0.79 | ALDH1A1 (0.43) | CYP3A4ALDH1A1TDP1LMNAMEN1 | |
| SCHEMBL3274456 | 0.78 | ALDH1A1 (0.42) | CYP3A4ALDH1A1TDP1LMNAMEN1 | |
| SCHEMBL2985136 | 0.78 | CYP3A4 (0.42) | CYP3A4ALDH1A1TDP1LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11725010-B2 | Polyheterocyclic compounds as METTL3 inhibitors | STORM THERAPEUTICS LIMITED (GB) | 2023-08-15 | — | — | US | disclosed |
| CN-109310602-B | Fragrance material | 高砂香料工业株式会社 | 2022-06-28 | — | — | CN | disclosed |
| CN-107207994-B | Photolabile acetal and ketal compounds for controlled release of active volatile carbonyl compounds | 弗门尼舍有限公司 | 2021-06-18 | — | — | CN | disclosed |
| WO-2004099200-A1 | ISOXAZOLE AND ISOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2004-11-18 | — | — | WO | disclosed |
| US-4338469-A | PAINT ADDITIVE | SUNTECH, INC. (US) | 1982-07-06 | — | — | US | disclosed |
| US-4292219-A | Latex-base paint containing 2-methoxy-2-phenyl propane or 8-methoxy-p-menthane | SUNTECH, INC. (PA) | 1981-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11725010-B2 | Polyheterocyclic compounds as METTL3 inhibitors | METTL3, DIMT1, TPMT | CYP3A4 2615/4885ALDH1A1 2056/4885TDP1 1158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.